Class Action Filed Against Unicycive Therapeutics, Inc.
In an important development for investors, a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers. This lawsuit arises during a period when the company was actively working on the approval of its new drug, oxylanthanum carbonate (OLC), targeting the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The case has been filed in the United States District Court for the Northern District of California.
Background of the Lawsuit
The class action, filed under identification number 25-cv-06923, represents all individuals and entities who purchased or acquired Unicycive securities between specific dates, alleging that the defendants violated federal securities laws. The complainants seek recovery for damages incurred due to alleged deception perpetrated by Unicycive and its executives regarding the company’s readiness and compliance with regulatory requirements set by the U.S. Food and Drug Administration (FDA).
Investors' Rights and Next Steps
If you are an investor who obtained Unicycive securities during the class period, it is crucial to know that you have a limited timeframe to act. This empowers you to petition the Court to appoint you as the Lead Plaintiff. Interested parties can seek further information regarding the Complaint through the appropriate channels established by Pomerantz LLP, a firm recognized for its expertise in securities litigation.
Unicycive's Mission and Business Model
Unicycive is a clinical-stage biotechnology company dedicated to developing therapies aimed at satisfying unmet medical needs. A key product in their pipeline is OLC, which is positioned as an innovative solution for managing phosphate levels in kidney disease patients. The company has maintained a promising outlook regarding the approval of its New Drug Application (NDA) for OLC, assuring investors of its capability to address FDA stipulations.
The Regulatory Journey of OLC
In September 2024, Unicycive took a significant step by submitting the NDA to the FDA. However, this journey has not been without its hurdles. The lawsuit alleges that the company's public statements regarding its readiness for regulatory compliance were misleading. Investors were purportedly assured of the legitimacy of its operations concerning manufacturing processes, which were later called into question.
Recent Developments Impacting Stock Value
On June 10, 2025, Unicycive experienced a sharp decline in stock price following a public announcement that the FDA had identified compliance deficiencies at a third-party manufacturing vendor. Following this disclosure, Unicycive's stock plummeted by approximately 40.89%, indicating a significant loss of investor confidence.
A subsequent announcement on June 30, 2025, revealed that the FDA issued a Complete Response Letter for the OLC NDA, further compounding investor concerns. This letter cited previous manufacturing deficiencies as the reasons for regulatory rejection, leading to another substantial drop in stock value. Investors remain apprehensive about the company's future following these disclosures.
About Pomerantz LLP
Pomerantz LLP, with its strong presence across major global cities, operates as a premier law firm specializing in corporate, securities, and antitrust class action litigation. Established over 85 years ago, the firm has been at the forefront of class action laws, advocating tirelessly for victims of securities fraud and corporate malfeasance. Their track record speaks volumes, having successfully recovered billions in damages over the years.
Contacting Pomerantz LLP
If you wish to inquire more about the class action or seek representation, please consider reaching out to Danielle Peyton, an attorney with Pomerantz LLP, through the provided contact method. It’s advised that those interested include their contact information along with details of their investments.
Frequently Asked Questions
What is the nature of the class action against Unicycive?
The class action claims that Unicycive and certain officers misled investors regarding the company's compliance with FDA regulations, impacting stock values.
How can investors participate in this class action?
Investors who acquired Unicycive securities during the class period may petition the court to become a Lead Plaintiff before the specified deadline.
What are the implications of the FDA's Complete Response Letter?
The Complete Response Letter indicates that the FDA found deficiencies in Unicycive's manufacturing processes, leading to regulatory challenges for their proposed drug.
What should investors do if they incurred losses?
It is advisable for investors to seek legal advice and possibly join the lawsuit to seek recovery for their losses due to alleged misinformation by the company.
Who can be contacted for more information?
Investors can reach out to Pomerantz LLP for detailed information regarding the class action and how to become involved.
